Results 101 to 110 of about 67,793 (197)
Long‐Term Outcomes After Slowly Resorbable P4HB Mesh Implantation: A Multicenter Analysis From European Registry
World Journal of Surgery, EarlyView.Fully resorbable biosynthetic mesh composed of poly‐4‐hydroxybutyrate (P4HB), have been designed for incisional hernia (IH) repair, including in contaminated surgical fields. While existing studies have demonstrated its safety and efficacy in the short term, comprehensive long‐term data, particularly after complete mesh resorption, remain scarce ...Rudolf van den Berg, Marie Wieser, Manuel López‐Cano, José Bueno‐Lledó, Ferdinand Köckerling, Grigorios Chatzimavroudis, Constanza Gonella‐Pacchiotti, Cesare Stabilini, Pablo Ortega‐Deballon, Benoit Romain, on behalf of PRS Group (Phasix Research Study Group), Giorgio Soliani, Lars N. Jorgensen, Jose Antonio Pereira Rodriguez, Jean‐François Gillion, Vincent Dubuisson, Niki Christou, Yohann Renard, David Moszkowicz, Guillaume Péré, Gregory Baud, Guillaume Passot, Benjamin Barrat, J. Jeekel +23 morewiley +1 more sourceCorrection: Collaborative neurocardiology board meetings for decision-making in stroke care: a real-world experience. [PDF]
Neurol Res PractMafael V, Buck T, Stengl H, Hellwig S, Klammer MG, Endres M, Reinthaler M, Barbieri F, Audebert HJ, Leistner DM, Landmesser U, Doehner W, Skurk C, Scheitz JF. +13 moreeuropepmc +1 more sourceChanges over time in hallucinogen‐related emergency department visits in Ontario, Canada
Addiction, EarlyView.Abstract Background and aims
Recent increasing interest in hallucinogens has underscored the critical gaps in our understanding of their adverse health effects and healthcare usage over time. The current study aimed to examine changes in emergency department (ED) visit rates involving hallucinogens, clinical outcomes of visits and the characteristics ...Daniel T. Myran, Rachael MacDonald‐Spracklin, Alexander R. Levesque, Michael Pugliese, Jess G. Fiedorowicz, André J. McDonald, Joshua D. Rosenblat, Ian Colman, Josephine Zein, Marco Solmi +9 morewiley +1 more sourceAllergic Rhinitis and Its Impact on Asthma (ARIA)‐EAACI Guidelines—2024–2025 Revision: Part I—Guidelines on Intranasal Treatments
Allergy, EarlyView.ABSTRACT Background
Allergic rhinitis (AR) impacts quality of life, work and school productivity. Over the last years, an important body of evidence resulting from mHealth data has led to a better understanding of AR. Such advances have motivated an EAACI‐endorsed update of the Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines (ARIA 2024 ...Bernardo Sousa‐Pinto, Jean Bousquet, Rafael José Vieira, Holger J. Schünemann, Torsten Zuberbier, Antonio Bognanni, Alkis Togias, Boleslaw Samolinski, Arunas Valiulis, Sian Williams, Anna Bedbrook, Wienczyslawa Czarlewski, Maria Jose Torres, Mohamed H. Shamji, Mário Morais‐Almeida, G. Walter Canonica, Leticia de las Vecillas, Mark S. Dykewicz, Cristina Jacomelli, Ludger Klimek, Lucas Leemann, Olga Lourenço, Yuliia Palamarchuk, Nikolaos G. Papadopoulos, Ana Margarida Pereira, Marine Savouré, Sanna K. Toppila‐Salmi, Maria Teresa Ventura, Juan José Yepes‐Nuñez, Alvaro A. Cruz, Giorgio Ciprandi, Bilun Gemicioglu, Mattia Giovannini, Brigita Gradauskiene, Tuomas Jartti, Miloš Jeseňák, Piotr Kuna, Violeta Kvedariene, Désirée E. Larenas‐Linnemann, Amir HA Latiff, Yousser Mohammad, Ken Ohta, Padukudru A. Mahesh, Isabella Pali‐Schöll, Oliver Pfaar, Frederico S. Regateiro, Nicolas Roche, Luís Taborda‐Barata, Charlotte Suppli Ulrik, Marylin Valentin Rostan, Giovanni Viegi, Luo Zhang, Tari Haahtela, Ivan Cherrez‐Ojeda, Juan Carlos Ivancevich, Nikolai Khaltaev, Arzu Yorgancioglu, Baharudin Abdullah, Mona Al‐Ahmad, Maryam Ali Al‐Nesf, Rita Amaral, Julijana Asllani, Karl‐C Bergmann, Jonathan A. Bernstein, Michael S. Blaiss, Fulvio Braido, Paulo Camargos, Pedro Carreiro‐Martins, Thomas Casale, Lorenzo Cecchi, Alessandro Fiocchi, Antonio F. M. Giuliano, George Christoff, Ieva Cirule, Jaime Correia de Sousa, Elisio M. Costa, Stefano Del Giacco, Philippe Devillier, Dejan Dokic, Elham Hossny, Tomohisa Iinuma, Carla Irani, Zhanat Ispayeva, Kaja Julge, Igor Kaidashev, Kazi S. Bennoor, Helga Kraxner, Inger Kull, Marek Kulus, Maciej Kupczyk, Andriy Kurchenko, Stefania La Grutta, Neven Miculinic, Lan Le Thi Tuyet, Michael Makris, Branislava Milenkovic, Sang Min Lee, Stephen Montefort, Andre Moreira, Joaquim Mullol, Rachel Nadif, Alla Nakonechna, Hugo E. Neffen, Marek Niedoszytko, Dieudonné Nyembue, Robyn E. O'Hehir, Ismail Ogulur, Yoshitaka Okamoto, Heidi Olze, Oscar Palomares, Petr Panzner, Vincenzo Patella, Ruby Pawankar, Constantinos Pitsios, Todor A. Popov, Francesca Puggioni, Santiago Quirce, Agné Ramonaité, Marysia Recto, Maria Susana Repka‐Ramirez, Graham Roberts, Karla Robles‐Velasco, Menachem Rottem, Marianella Salapatas, Joaquin Sastre, Nicola Scichilone, Juan‐Carlos Sisul, Dirceu Solé, Manuel E. Soto‐Martinez, Milan Sova, Pongsakorn Tantilipikorn, Ana Todo‐Bom, Vladyslav Tsaryk, Ioanna Tsiligianni, Marilyn Urrutia‐Pereira, Erkka Valovirta, Tuula Vasankari, Dana Wallace, De Yun Wang, Margitta Worm, Osman M. Yusuf, Mihaela Zidarn, Sara Gil‐Mata, Manuel Marques‐Cruz, Bassam Mahboub, Ignacio J. Ansotegui, Antonino Romano, Werner Aberer, Maria Cristina Artesani, Elena Azzolini, Bruno Barreto, Joan Bartra, Sven Becker, Bianca Beghe, Attilio Boner, Ewa Borowiack, Jacques Bouchard, Melisande Bourgoin‐Heck, Luisa Brussino, Roland Buhl, José Antonio Castillo‐Vizuete, Denis Charpin, Niels H. Chavannes, Marta Chełmińska, Lei Cheng, Ekaterine Chkhartishvili, Seong H. Cho, Herberto Jose Chong‐Neto, Deepa Choudhury, Derek K. Chu, Cemal Cingi, Enrico Compalati, Raquel Albuquerque Costa, Olga Mariana Cunha, Biljana Cvetkovski, Victoria Cardona‐Dahl, Gennaro D'Amato, Janet Davies, Danilo Di Bona, Sandra N. Gonzalez Diaz, Maria V. Dimou, Maria Doulaptsi, Renato Ferreira‐da‐Silva, Radoslaw Gawlik, Mario Calvo‐Gil, Ozlem Goksel, Maximiliano R. Gómez, Maia Gotua, Christos Grigoreas, Ineta Grisle, Maria Antonieta Guzman, Rachel House Tan, Michael Hyland, Despo Ierodiakonou, Aspasia Karavelia, Paul Keith, Marta Kisiel, Tanja Soklic Kosak, Mitja Kosnik, Ilgim Vardaloglu Koyuncu, Vicky Kritikos, Justyna Litynska, Carlo Lombardi, Gilles Louis, Matteo Martini, Cem Meço, Eris Mesonjesi, Florin Mihaltan, Marcin Moniuszko, Robert N. Naclerio, Kari C. Nadeau, Sophia Neisinger, Markus Ollert, Michal Ordak, Giovanni Paoletti, Hae‐Sim Park, Elena Parmelli, Edgar Arturo Perdomo‐Flores, José Miguel Fuentes Pérez, Nhan Pham‐Thi, Emmanuel Prokopakis, Inês Ribeiro‐Vaz, Giovanni Rolla, Jan Romantowski, Philippe Rombaux, Philip W. Rouadi, Maia Rukhadze, Dermot Ryan, Ewelina Sadowska, Daiju Sakurai, Laila Salameh, Faradiba Serpa Sarquis, Elie Serrano, Jane Da Silva, Michael Soyka, Krzysztof Specjalski, Vesna Tomic‐Spiric, Katarina Stevanovic, Abirami Subramaniam, Maria Do Ceu Teixeira, Tuuli Thomander, Martina Vachova, Marianne van Hage, Pakit Vichyanond, Martin Wagenmann, Fanny Wai San Ko, Pascal Werminghaus, Paraskevi Vicky Xepapadaki, Yi‐Kui Xiang, Qintai Yang, Daniela Rivero Yeverino, Jaron Zuberbier, João A. Fonseca +252 morewiley +1 more sourceLong‐Term Efficacy and Safety of Ligelizumab as Re‐Treatment in Patients With Chronic Spontaneous Urticaria
Allergy, EarlyView.Ligelizumab re‐treatment in CSU patients showed sustained efficacy and tolerability. Over 50% achieved symptom control (UAS7 ≤ 6) by Week 12; benefits maintained through Week 52. No new safety signals observed; aligns with prior PEARL trial outcomes. CSU, chronic spontaneous urticaria; mg, milligram; q4w, every 4 weeks; UAS, urticaria activity score ...Ana M. Gimenez‐Arnau, Marcus Maurer, Adam Reich, Chia‐Yu Chu, Diana Deleanu, Gordon Sussman, Jorge Sanchez, Knut Brockow, Koremasa Hayama, Michihiro Hide, Mohamed Denguezli, Raisa Meshkova, Roberta F. J. Criado, Sarbjit Saini, Solange Valle, Eva Hua, Pengpeng Wang, Alis Burciu, Isabelle Indermuehle, Vineeth Varanasi, Yolandi Joubert, Thomas Severin, Manmath Patekar +22 morewiley +1 more sourceUnmet Needs in Treatment Escalation for Chronic Spontaneous Urticaria: Findings From the CURE Registry
Allergy, EarlyView.Appropriate treatment escalation improves CSU disease control. However, only about a quarter of patients achieve a complete response, the main goal of CSU treatment. Approximately one‐third of patients clinically eligible for escalation (UCT < 12) do not receive guideline‐recommended treatment escalation and remain symptomatic on their current ...Pavel Kolkhir, Pascale Salameh, Magdalena Zajac, Alicja Kasperska‐Zajac, Ana Giménez‐Arnau, Maria Puertolas, Hanna Bonnekoh, Carolina Vera Ayala, Michael Makris, Eleni Chatzidimitriou, Stamatios Gregoriou, Kanokvalai Kulthanan, Andrea Bauer, Mojca Bizjak‐Suran, Daria Fomina, Alexis Bocquet, Joachim Dissemond, Mohamed Abuzakouk, Tara Raftery, Nadine Chapman‐Rothe, Emek Kocatürk, Clive Grattan, Riccardo Asero, Jonny G. Peter, Simon Francis Thomsen, Karsten Weller +25 morewiley +1 more source
